ArticleInflammopharmacology2026
Neuroprotective effects of dapansutrile in rotenone-induced parkinsonism: targeting NLRP3/caspase-1, NF-κB, Nrf2/HO-1, and PINK1/Parkin pathways.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic dysfunction, neuroinflammation, oxidative stress, and mitochondrial abnormalities. Activation of the NLRP3 inflammasome has been implicated in PD pathophysiology; however, its relationship with other pathological processes remains incompletely understood. The present study investigated the neuroprotective effects of dapansutrile (DPST), a selective NLRP3 inhibitor, in a rotenone (ROTN)-induced rat model of parkinsonism and examined its effects on inflammation-, oxidative stress-, mitophagy-, and apoptosis-related markers.
methodsForty-four adult male Wistar rats were randomly allocated into four groups: control, DPST-treated control (200 mg/kg/day, p.o.), ROTN-treated (1.5 mg/kg, s.c., every other day for 21 days), and ROTN + DPST-treated groups. Behavioral assessments were conducted followed by biochemical, molecular, histopathological, and immunohistochemical analyses of brain tissues. Markers related to oxidative stress, inflammatory signaling, mitophagy-associated pathways, and apoptosis-associated signaling were evaluated.
resultsROTN administration induced marked behavioral deficits, dopamine depletion, oxidative stress, neuroinflammation, histopathological alterations, and increased GFAP immunoreactivity. These changes were accompanied by increased NLRP3 expression, caspase-1 activity, IL-18 levels, and Apaf-1 expression, together with reduced PINK1, Parkin, and MFN1 protein expression. DPST treatment significantly improved behavioral performance, restored dopamine and BDNF levels, attenuated oxidative stress and inflammatory responses, reduced NLRP3-associated inflammatory markers, improved the expression of PINK1-, Parkin-, and MFN1-related proteins, and lowered Apaf-1 expression. Furthermore, DPST ameliorated the histopathological alterations and astroglial activation induced by ROTN.
conclusionDPST exerted significant neuroprotective effects in the rotenone-induced rat model of parkinsonism. These beneficial effects were associated with modulation of NLRP3-associated inflammatory signaling, attenuation of oxidative stress, and alterations in mitophagy-related and apoptosis-related markers. While the findings support a potential role for NLRP3 signaling in ROTN-induced neurotoxicity, the present data establish associations rather than direct causal mechanisms. Further studies employing dedicated assessments of pyroptosis, mitophagic flux, mitochondrial function, apoptosis, and dopaminergic neuronal survival are required to clarify the mechanistic basis of DPST-mediated neuroprotection.
Indexed as
Identifiers
42816721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.